GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Shiller PE Ratio

SLN (Silence Therapeutics) Shiller PE Ratio : (As of Jul. 23, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Silence Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Silence Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Shiller PE Ratio Chart

Silence Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Silence Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Silence Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Silence Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Shiller PE Ratio falls into.


;
;

Silence Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Silence Therapeutics's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Silence Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.6/136.1000*136.1000
=-0.600

Current CPI (Mar. 2025) = 136.1000.

Silence Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201006 0.000 90.200 0.000
201012 0.000 91.700 0.000
201106 0.000 93.500 0.000
201112 0.000 95.000 0.000
201206 0.000 95.600 0.000
201212 0.000 97.300 0.000
201306 0.000 98.000 0.000
201312 0.000 99.200 0.000
201406 0.000 99.800 0.000
201412 0.000 99.900 0.000
201506 0.000 100.100 0.000
201512 0.000 100.400 0.000
201606 0.000 101.000 0.000
201612 0.000 102.200 0.000
201706 0.000 103.500 0.000
201712 0.000 105.000 0.000
201806 0.000 105.900 0.000
201812 0.000 107.100 0.000
201906 0.000 107.900 0.000
201912 0.000 108.500 0.000
202006 0.000 108.800 0.000
202009 -0.425 109.200 -0.530
202012 -0.674 109.400 -0.838
202103 -0.400 109.700 -0.496
202106 -0.544 111.400 -0.665
202109 -0.447 112.400 -0.541
202112 -0.432 114.700 -0.513
202203 -0.339 116.500 -0.396
202206 -0.484 120.500 -0.547
202209 -0.241 122.300 -0.268
202212 -0.595 125.300 -0.646
202303 -0.353 126.800 -0.379
202306 -0.363 129.400 -0.382
202309 -0.271 130.100 -0.283
202312 -0.504 130.500 -0.526
202403 -0.060 131.600 -0.062
202406 -0.421 133.000 -0.431
202409 -0.767 133.500 -0.782
202412 0.307 135.100 0.309
202503 -0.600 136.100 -0.600

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Silence Therapeutics  (NAS:SLN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Silence Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.